Jonathan Graham compensation by year
Amgen Summary Compensation Table · all 4 fiscal years held| Component | FY2016 | FY2017 | FY2018 | FY2019 |
|---|---|---|---|---|
| Salary | $916,789 | $932,577 | $938,596 | $959,113 |
| Bonus | $1,000,000 | $0 | $0 | $0 |
| Stock awards | $1,609,898 | $1,749,939 | $1,959,878 | $3,959,666 |
| Option awards | $689,990 | $749,997 | $839,983 | $839,997 |
| Non-equity incentive | $1,165,000 | $858,000 | $1,402,000 | $1,220,000 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 |
| All other | $1,038,668 | $231,695 | $204,901 | $261,194 |
| Total | $6,420,345 | $4,522,208 | $5,345,358 | $7,239,970 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Amgen Inc. DEF 14A filed April 7, 2020, accession 0001193125-20-100447, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Amgen Inc. filed document, accession 0001193125-20-100447. Every figure is read from that document and cited to the page and table it appears in. Filed April 7, 2020.
Equity holdings
unvested awards at FY2019 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 19,109 | $4,606,607 | — |
| PSU | 15,593 | $3,759,005 | — |
| PSU | 15,180 | $3,659,443 | — |
| PSU | 11,600 | $2,796,412 | — |
| Option | 18,247 | — | $162.60 |
| Option | 8,516 | — | $156.35 |
| Option | 27,568 | — | $177.31 |
| Option | 24,291 | — | $177.46 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Amgen Inc.'s FY2019 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
35 Form 4 lines since the FY2019 proxy (filed April 7, 2020)current to 2026-11-21 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-05-07 | Tax withholding | — | 499 | $331.11 | 39,712 |
| 2026-05-06 | Tax withholding | — | 408 | $329.59 | 40,211 |
| 2026-05-05 | Grant or award derivative | — | 17,022 | $329.59 | 17,022 |
| 2026-05-05 | Grant or award | — | 2,609 | $0.00 | 40,619 |
| 2026-05-02 | Tax withholding | — | 647 | $329.82 | 38,620 |
| 2026-05-02 | Tax withholding | — | 610 | $329.82 | 38,010 |
| 2026-03-16 | Tax withholding | — | 5,353 | $366.21 | 39,267 |
| 2026-03-03 | Grant or award | — | 10,723 | $0.00 | 44,478 |
The 8 most recent of 35 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Amgen’s named executive officers, FY2019
as the company reported each| Named executive officer | Role | FY2019 total |
|---|---|---|
| Robert A. Bradway | Chief Executive Officer and President | $19,612,793 |
| Jonathan Graham · this page | Executive Vice President, General Counsel and Secretary | $7,239,970 |
| David Meline | Executive Vice President and Chief Financial Officer | $6,673,570 |
| Murdo Gordon | Executive Vice President, Global Commercial Operations | $6,655,836 |
| David M. Reese | Executive Vice President, Research and Development | $6,537,925 |
The full Amgen compensation record
free company briefThis page is one person within Amgen's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Amgen proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Amgen's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.